Adial Pharmaceuticals (ADIL) Q3 2026 earnings summary

Executive summary

• Strategic focus shifted to AT177, a colon-targeted AhR agonist for ulcerative colitis; AD04 development for alcohol use disorder was discontinued absent non-dilutive funding or a partner.

• AT177 remains in IND-enabling studies, with GMP manufacturing initiated; IND submission and Phase 1a SAD/MAD initiation are planned for H1 2027, subject to regulatory clearance.

• The June acquisition and financing reshaped operations and capital structure; the Azora Therapeutics name and AZR Nasdaq trading became effective October 29, 2026.

Financial highlights

• Q3 2026 operating expenses and operating loss were $7.531M, vs. $1.764M; net loss was $64.562M, vs. $1.794M, including a $57.108M non-cash milestone warrant fair-value charge.

• Q3 R&D expense was $1.775M, including $863K for AT177 and $18K for AD04; G&A was $5.8M, reflecting preclinical work, merger and integration costs, stock compensation and severance.

• 9M 2026 operating expenses were $61.558M vs. $5.914M; net loss was $118.574M vs. $5.981M, including $46.185M acquired IPR&D expense.

• 9M R&D expense was $2.648M, including $966K for AT177 and $233K for AD04; G&A was $12.725M, largely reflecting preclinical, merger, integration, equity and severance costs.

• No significant product revenue to date; accumulated deficit was $208.5M at September 30, 2026, vs. $90.0M at December 31, 2025.

Outlook and guidance

• IND submission and Phase 1a SAD/MAD initiation are planned for H1 2027; initial UC proof-of-concept data are anticipated in H1 2028, subject to regulatory clearance.

• Existing cash is expected to fund IND-enabling studies and Phase 1a, assuming no milestone warrant proceeds; Phase 1b is excluded and requires additional funding.

• Phase 1b UC proof-of-concept is planned after Phase 1a; potential funding includes milestone warrant purchases or other sources, but no committed funding exists and investors are not obligated to participate.

• R&D spending is expected to increase as clinical development advances; product-sales revenue is not expected before development and regulatory approval, which may take years.